Imagine If Doctors Could Practice Medicine

Imagine a world where pharmaceutical companies had no influence over the FDA, legislatures, or medical boards.

Now imagine a physician sitting across from a patient who has tried the standard options and wants to discuss a peptide. The doctor reviews the research, draws on years of clinical experience, explains what remains uncertain, and decides with the patient whether treatment makes sense. They agree on what to measure, what risks to watch for, and when to stop if it is not helping.

Apparently, in this imaginary world, doctors practice medicine.

I am not arguing that every peptide works. I am not arguing that a patient feeling better proves a treatment is safe. And I certainly want to know what is in a vial before anyone injects it.

I am asking a different question: What would peptide policy look like if physician judgment and patient outcomes carried more weight than the interests of companies that already dominate the drug market?

Perhaps we would build a clear path for physicians to use reliably sourced products while documenting outcomes and reporting problems. Perhaps we would be honest with patients about the limits of the evidence while allowing careful clinical experience to help generate more of it. Perhaps we would trust a physician to distinguish a promising treatment from an expensive vial with excellent branding.

Instead, physicians and patients are often told to wait for certainty. But certainty is not the standard medicine uses for every difficult decision. Doctors make decisions with incomplete information every day. Their training, experience, and observation of actual patients are part of how they do it.

Of course, physician discretion still needs guardrails. Product quality matters. Informed consent matters. Evidence matters. So do adverse events and results that disappoint. A responsible physician should welcome scrutiny of all of them.

What deserves scrutiny, too, is a system where the largest drug companies have a seat at the policy table while independent physicians are asked to justify every step they take outside the established playbook.

The recent FDA advisory vote on peptides does not give clinics permission to start offering them. The legal sourcing and compounding rules still apply. But it does give us an opportunity to ask what comes next.

In a world built around patients, the answer would involve good evidence, dependable products, informed choice, and physicians who are free to use their knowledge and learn from their results.

I would like to live in that world.

This article is commentary, not legal or medical advice for a particular practice or patient.